BioWorld Science

Nov. 21, 2017

View Archived Issues

ITUS enters research agreement with Moffitt Cancer Center

Read More

European Commission approves Tesaro's Zejula

Read More

Genexine's recombinant human erythropoietin effective in patients on dialysis

Read More

Selective nSMase2 inhibitor MS-882 shows promise for Alzheimer's disease

Read More

Orexo's Zubsolv approved for opioid dependence in Europe

Read More

FDA orphan and breakthrough therapy designations awarded to PellePharm for patidegib

Read More

FDA grants breakthrough therapy designation to patisiran

Read More

Indication for Zytiga expanded in Europe

Read More

FDA gives fast track status to lumateperone for treatment of schizophrenia

Read More

CX-549's neuroprotective effects demonstrated in a rat model of stroke

Read More

OphthaliX completes merger with Wize Pharma

Read More

FDA grants orphan drug designation to Revance's daxibotulinumtoxin A for cervical dystonia

Read More

Adocia reports phase I results for BioChaperone Glucagon

Read More

Melinta Therapeutics presents compounds for treating bacterial infections

Read More

Janssen applies to expand indication for Imbruvica in Japan

Read More

Novel glucosylceramidase activators presented by Lysosomal Therapeutics

Read More

Full U.S. commercial launch for Zilretta

Read More

Incyte discloses hPD-1 signaling inhibitors

Read More

First patient enrolled in pivotal study of Daiichi Sankyo's DS-8201

Read More

EMA announces relocation to the Netherlands

Read More

Calliditas Therapeutics gives update on phase III study plans for Nefecon

Read More

Calico Life Sciences and AbbVie patent new EIF2B activators

Read More

Bayer Pharma identifies vasopressin receptor antagonists

Read More